甲状腺癌与糖尿病的相关性研究进展

doi:10.16352/j.issn.1001-6325.2022.04.014

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (4): 667-670.doi: 10.16352/j.issn.1001-6325.2022.04.014

甲状腺癌与糖尿病的相关性研究进展

傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞^*

中南大学湘雅医院老年内分泌科, 湖南长沙 410008

收稿日期:2021-10-15 修回日期:2022-12-31 出版日期:2022-04-05 发布日期:2022-04-01
通讯作者: * lhx900@aliyun.com
基金资助:
国家自然科学基金(81873672)

Research progress of correlation between thyroid cancer and diabetes mellitus

FU Jing-lan, DENG Yuan-yuan, ZHANG Ying, ZHANG Xin-xu, CHEN Shi-jing, LIU Hui-xia^*

Department of Geriatric Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China

Received:2021-10-15 Revised:2022-12-31 Online:2022-04-05 Published:2022-04-01
Contact: * lhx900@aliyun.com

摘要/Abstract

摘要： 甲状腺癌(TC)是内分泌系统最常见的恶性肿瘤,糖尿病(DM)是由胰岛β细胞功能障碍或胰岛素抵抗所导致的慢性代谢性疾病。近年来,随着TC与DM的患病率明显上升,众多研究表明这两种疾病发生发展之间存在相关性。

关键词: 甲状腺癌, 糖尿病, 降糖药

Abstract: Thyroid cancer (TC) is the most common malignant tumor of the endocrine system. Diabetes mellitus (DM) is a chronic metabolic disease caused by pancreatic β-cell dysfunction or insulin resistance. In recent years, with the increased morbidity of TC and DM , many studies have shown potential relationship between the occurrence and development of these two diseases.

Key words: thyroid cancer, diabetes mellitus, hypoglycemic drugs

中图分类号:

R736.1

傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞. 甲状腺癌与糖尿病的相关性研究进展[J]. 基础医学与临床, 2022, 42(4): 667-670.

FU Jing-lan, DENG Yuan-yuan, ZHANG Ying, ZHANG Xin-xu, CHEN Shi-jing, LIU Hui-xia. Research progress of correlation between thyroid cancer and diabetes mellitus[J]. Basic & Clinical Medicine, 2022, 42(4): 667-670.

参考文献

[1] Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16: 17-29.
[2] Aschebrook-Kilfoy B, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study[J]. Thyroid, 2011, 21: 957-963.
[3] Linkeviciute-Ulinskiene D, Patasius A, Zabuliene L, et al. Increased risk of site-specific cancer in people with type 2 diabetes: anational cohort study[J]. Int J Environ Res Public Health, 2019, 17: 246.doi:10.3390/ijerph17010246.
[4] Zubcic Z, Sestak A, Mihalj H, et al. The association between type 2 diabetes mellitus, hypothyroidism, and thyroid cancer[J]. Acta Clin Croat, 2020, 59: 129-135.
[5] 邓媛媛,柯飒,刘慧霞,等.甲状腺癌合并糖尿病患者的临床病理特征分析[J].中国普通外科杂志,2020,29:565-573.
[6] Zhang X, Sheng X, Miao T, et al. Effect of insulin on thyroid cell proliferation, tumor cell migration, and potentially related mechanisms[J]. Endocr Res, 2019, 44: 55-70.
[7] Zhao J, Wen J, Wang S, et al. Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies[J]. BMC Cancer, 2020, 20: 788.doi: 10.1186/s12885-020-07299-x.
[8] Zhang G, Jiao Q, Shen C, et al. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer[J]. Cancer Sci, 2021, 112: 997-1010.
[9] Liotti F, Collina F, Pone E, et al. Interleukin-8, but not the related chemokine CXCL1, sustains an autocrine circuit necessary for the properties and functions of thyroid cancer stem cells[J]. Stem Cells, 2017, 35: 135-146.
[10] Yaribeygi H, Sathyapalan T, Atkin SL, et al. Molecular mechanisms linking oxidative stress and diabetes mellitus[J]. Oxid Med Cell Longev, 2020, 2020: 8609213.doi:10.1155/2020/8609213.
[11] Tabur S, Aksoy SN, Korkmaz H, et al. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma[J]. Tumour Biol, 2015, 36: 2667-2674.
[12] Zhang Z, Xu T, Qin W, et al. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer[J]. Biochem Biophys Res Commun, 2020, 522: 21-25.
[13] Elgazar EH, Esheba NE, Shalaby SA, et al. Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus[J]. Diabetes Metab Syndr, 2019, 13: 2513-2517.
[14] Schiffmann L, Kostev K, Kalder M. Association between various thyroid gland diseases, TSH values and thyroid cancer: a case-control study[J]. J Cancer Res Clin Oncol, 2020, 146: 2989-2994.
[15] Song YS, Kim MJ, Sun HJ, et al. Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth[J]. Clin Cancer Res, 2019, 25: 414-425.
[16] Zou M, Baitei EY, Al-Rijjal RA, et al. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via down-regulation of p53 expression in papillary thyroid cancer[J]. Oncogene, 2016, 35: 1909-1918.
[17] Bidulescu A, Dinh PC, Sarwary S, et al. Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study[J]. BMC Endocr Disord, 2020, 20: 31. doi:10.1186/s12902-020-0511-z.
[18] Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells[J]. Oncol Rep, 2010, 23: 1721-1727.
[19] Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study[J]. Int J Cancer, 2018, 142: 1332-1342.
[20] Ye J, Qi L, Chen K, et al. Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo[J]. Int J Oncol, 2019, 55: 331-339.
[21] Cho YY, Kang MJ, Kim SK, et al. Protective effect of metformin against thyroid cancer development: apopulation-based study in Korea[J]. Thyroid, 2018, 28: 864-870.
[22] Li C, Kuang J, Zhao Y, et al. Effect of type 2 diabetes and antihyperglycemic drug therapy on signs of tumor invasion in papillary thyroid cancer[J]. Endocrine, 2020, 69: 92-99.
[23] Kebebew E, Lindsay S, Clark O, et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer[J]. Thyroid, 2009, 19: 953-956.
[24] Tseng C. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes[J]. Ann Med, 2013, 45: 539-544.
[25] Chen JY, Wang JJ, Lee HC, et al. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells[J]. J Chin Med Assoc, 2020, 83: 923-930.

甲状腺癌与糖尿病的相关性研究进展

Research progress of correlation between thyroid cancer and diabetes mellitus

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑天圣, 佟雪巍, 张伊桐, 朱敏, 詹晓蓉. 2型糖尿病心血管并发症发病机制的研究进展[J]. 基础医学与临床, 2022, 42(5): 814-817.
[2]	胡贤良, 万燕, 冯霁. 肠道菌群在妊娠期糖尿病发病中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 516-519.
[3]	郭梦然, 闵行, 叶月, 许晓双, 甄东户. 单核苷酸多态性和免疫细胞在糖尿病肾脏疾病中的研究进展[J]. 基础医学与临床, 2022, 42(2): 335-339.
[4]	谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.
[5]	郑杨, 魏海军, 申嘉陵, 刘润禹, 刘勇, 孙晓磊. MVBs及IL-1β在2型糖尿病大鼠血管钙化中的作用[J]. 基础医学与临床, 2022, 42(2): 208-214.
[6]	邓九红, 郑超, 王声遥, 王心怡. 醋酸泼尼松对糖尿病肾病模型大鼠肾功能、肾脏炎性反应及AMPK/SIRT1信号通路的影响[J]. 基础医学与临床, 2022, 42(2): 243-248.
[7]	钱子冰刘静曾佩芸张琦. mTOR调控自噬参与糖尿病并发症的研究进展[J]. 基础医学与临床, 2021, 41(8): 1200-1204.
[8]	矫立杰, 魏亚新, 李鸿珠. 硫化氢通过抑制氧化应激减轻糖尿病心肌病病变[J]. 基础医学与临床, 2021, 41(5): 739-743.
[9]	边芳, 李宁, 李奇, 李康, 金雯. 膜联蛋白A1减轻1型糖尿病小鼠微血管并发症[J]. 基础医学与临床, 2021, 41(4): 484-489.
[10]	刘亚琪, 郑承红. miR-205通过靶向调控Wnt-5a抑制乳头状甲状腺癌的细胞增殖[J]. 基础医学与临床, 2021, 41(3): 358-363.
[11]	陈英, 袁丽, 李饶, 杨小玲. 糖尿病足患者压力性损伤危险现状调查及影响因素分析[J]. 基础医学与临床, 2021, 41(2): 254-256.
[12]	孙明玥, 李旭妍, 萨如拉, 李晶晶, 梁浩, 闫朝丽, 苏燕. 2型糖尿病患者红细胞变形能力改变与RBC能量代谢相关[J]. 基础医学与临床, 2021, 41(2): 245-249.
[13]	李梦婕柯本龙脉房向东. 线粒体融合蛋白Mfn2在糖尿病肾病中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1823-1827.
[14]	杨静李民. SIRT3介导的线粒体功能和代谢调控机制在2型糖尿病中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1828-1832.
[15]	王梦伊李倩竹张世武舒凤张伟华. 线粒体转运系统和降解系统的研究进展[J]. 基础医学与临床, 2021, 41(10): 1523-1528.